Exscientia vs Recursion Pharmaceuticals

Recursion Pharmaceuticals has a disclosed valuation of $2.2B, while Exscientia's valuation is not publicly available, making a direct size comparison difficult. Recursion Pharmaceuticals employs 800 people.

Exscientia has raised $500M in disclosed funding across 0 known rounds. Recursion Pharmaceuticals's funding history is not publicly available.

Exscientia holds the higher Awaira Score at 72/100, compared to Recursion Pharmaceuticals's 65/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 7-point gap that reflects meaningful differences in scale or traction.

Exscientia was founded by Andrew Hopkins in 2012. Recursion Pharmaceuticals was founded by Chris Gibson in 2013. Visit each company's profile on Awaira for a full founder biography.

Exscientia: Exscientia is an AI-driven drug design company that uses automated design-make-test-analyse cycles to generate drug candidates with the goal of reducing the time and cost of small molecule drug discovery. The Oxford-originated company builds generative chemistry models and automated laboratory robotics that together create a closed-loop system for molecular design, synthesis, and assay testing, producing candidates in months rather than the years required by conventional medicinal chemistry programmes.\n\nThe company went public on NASDAQ under the ticker EXAI, having raised over $500 million in combined public and private funding from investors including Bristol-Myers Squibb, Celgene, SoftBank, and GT Healthcare Capital Partners. Exscientia has clinical-stage programmes in oncology and neuropsychiatry and reports being the first company to advance AI-designed drug candidates into human clinical trials. The company has multiple pharma partnerships including agreements with Bristol-Myers Squibb, Sanofi, and Evotec that provide milestone and royalty revenue.\n\nExscientia competes in the AI drug design space against Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics, and Insilico Medicine. The company differentiates through its integrated automated laboratory approach, which combines computational design with physical synthesis and testing in a single workflow rather than treating AI design as a separate step before conventional chemistry. Its public market position and disclosed clinical programmes provide transparency benchmarks against which the broader AI drug discovery sector is measured by investors and pharmaceutical partners. Recursion Pharmaceuticals: Recursion Pharmaceuticals is a computational biology company founded in 2013 that uses artificial intelligence and high-throughput screening to accelerate drug discovery and development. The company's platform combines automated microscopy, machine learning, and large-scale biological data analysis to identify novel drug candidates and therapeutic targets across multiple disease areas. Recursion operates a proprietary laboratory automation system capable of conducting millions of experiments to map cellular and molecular responses to chemical compounds. The company has developed computational models to predict drug efficacy and safety profiles before traditional clinical testing, significantly reducing development timelines and costs. As a publicly traded company with a $2.2 billion valuation, Recursion has built partnerships with major pharmaceutical firms including Bayer and Exscientia to validate its platform's effectiveness. The company's approach focuses on rare genetic diseases and oncology, leveraging its ability to process vast biological datasets that would be impractical through conventional methods. Recursion's competitive advantage lies in its integration of wet laboratory automation with advanced machine learning analytics, enabling systematic drug discovery at scale. The company continues to expand its internal pipeline while licensing its technology to established pharma players, positioning itself as both a drug developer and a computational biology platform provider in the AI healthcare sector. Recursion combines automated laboratory systems with machine learning to systematize drug discovery at unprecedented scale and speed.

Exscientia was founded first in 2012, giving it 1 year of additional market experience. Recursion Pharmaceuticals was founded later in 2013. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Exscientia has approximately 100-500 employees, while Recursion Pharmaceuticals has approximately 800. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Exscientia and Recursion Pharmaceuticals are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.